Quadrant Capital Group’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $16.1K | Buy |
85
+1
| +1% | +$175 | ﹤0.01% | 2073 |
|
|
2025
Q4 | $14.3K | Hold |
84
| – | – | ﹤0.01% | 2110 |
|
|
2025
Q3 | $11.1K | Buy |
+84
| New | +$10.1K | ﹤0.01% | 2136 |
|
|
2025
Q2 | – | Sell |
-2,061
| Closed | -$256K | – | 1978 |
|
|
2025
Q1 | $256K | Buy |
2,061
+1,856
| +905% | +$242K | 0.01% | 1174 |
|
|
2024
Q4 | $25.2K | Buy |
205
+101
| +97% | +$11.9K | ﹤0.01% | 1773 |
|
|
2024
Q3 | $11.6K | Buy |
104
+6
| +6% | +$657 | ﹤0.01% | 2100 |
|
|
2024
Q2 | $10.5K | Sell |
98
-310
| -76% | -$34.1K | ﹤0.01% | 2103 |
|
|
2024
Q1 | $49.1K | Buy |
408
+8
| +2% | +$980 | ﹤0.01% | 1415 |
|
|
2023
Q4 | $49.2K | Sell |
400
-37
| -8% | -$4.62K | ﹤0.01% | 1399 |
|
|
2023
Q3 | $56.6K | Sell |
437
-118
| -21% | -$15.7K | 0.01% | 1194 |
|
|
2023
Q2 | $68.8K | Buy |
555
+204
| +58% | +$27.4K | 0.01% | 1088 |
|
|
2023
Q1 | $51.4K | Sell |
351
-161
| -31% | -$23.8K | 0.01% | 1227 |
|
|
2022
Q4 | $81.6K | Buy |
512
+297
| +138% | +$43.5K | 0.01% | 898 |
|
|
2022
Q3 | $29K | Buy |
215
+102
| +90% | +$15.5K | ﹤0.01% | 1341 |
|
|
2022
Q2 | $18K | Buy |
113
+24
| +27% | +$3.69K | ﹤0.01% | 1365 |
|
|
2022
Q1 | $14K | Buy |
89
+18
| +25% | +$2.61K | ﹤0.01% | 1498 |
|
|
2021
Q4 | $9K | Sell |
71
-88
| -55% | -$11.6K | ﹤0.01% | 1669 |
|
|
2021
Q3 | $21K | Buy |
159
+56
| +54% | +$8.46K | ﹤0.01% | 1226 |
|
|
2021
Q2 | $18K | Sell |
103
-3
| -3% | -$520 | ﹤0.01% | 1258 |
|
|
2021
Q1 | $17K | Sell |
106
-187
| -64% | -$30.8K | ﹤0.01% | 1252 |
|
|
2020
Q4 | $48K | Buy |
293
+222
| +313% | +$33.1K | 0.01% | 759 |
|
|
2020
Q3 | $10K | Buy |
71
+25
| +54% | +$3.1K | ﹤0.01% | 1224 |
|
|
2020
Q2 | $5K | Sell |
46
-40
| -47% | -$4.42K | ﹤0.01% | 1657 |
|
|
2020
Q1 | $8K | Sell |
86
-298
| -78% | -$38.5K | ﹤0.01% | 1497 |
|
|
2019
Q4 | $55K | Buy |
384
+348
| +967% | +$47.4K | 0.01% | 1288 |
|
|
2019
Q3 | $3K | Sell |
36
-1,048
| -97% | -$140K | ﹤0.01% | 2022 |
|
|
2019
Q2 | $153K | Buy |
1,084
+317
| +41% | +$42.6K | 0.02% | 677 |
|
|
2019
Q1 | $108K | Buy |
767
+681
| +792% | +$88.8K | 0.02% | 768 |
|
|
2018
Q4 | $9K | Buy |
86
+18
| +26% | +$2.67K | ﹤0.01% | 1422 |
|
|
2018
Q3 | $10K | Hold |
68
| – | – | ﹤0.01% | 1291 |
|
|
2018
Q2 | $10K | Hold |
68
| – | – | ﹤0.01% | 1259 |
|
|
2018
Q1 | $9K | Hold |
68
| – | – | ﹤0.01% | 1309 |
|
|
2017
Q4 | $9K | Buy |
68
+53
| +353% | +$7.35K | ﹤0.01% | 1221 |
|
|
2017
Q3 | $2K | Hold |
15
| – | – | ﹤0.01% | 1795 |
|
|
2017
Q2 | $2K | Hold |
15
| – | – | ﹤0.01% | 1593 |
|
|
2017
Q1 | $2K | Hold |
15
| – | – | ﹤0.01% | 1615 |
|
|
2016
Q4 | $1K | Buy |
15
+1
| +7% | +$111 | ﹤0.01% | 1718 |
|
|
2016
Q3 | $0 | Sell |
14
-13
| -48% | -$1.75K | ﹤0.01% | 2034 |
|
|
2016
Q2 | $0 | Buy |
27
+13
| +93% | +$1.92K | ﹤0.01% | 2023 |
|
|
2016
Q1 | $0 | Buy |
+14
| New | +$1.74K | ﹤0.01% | 1888 |
|
|
2015
Q4 | – | Sell |
-29
| Closed | -$2K | – | 1637 |
|
|
2015
Q3 | $2K | Hold |
29
| – | – | ﹤0.01% | 963 |
|
|
2015
Q2 | $4K | Buy |
+29
| New | +$5.21K | ﹤0.01% | 871 |
|
Other funds holding JAZZ
VPM
VCM
EC
Quadrant Capital Group's JAZZ Position: Q1 2026 in Review
Quadrant Capital Group increased its Jazz Pharmaceuticals (JAZZ) stake by 1.2% in Q1 2026, buying an estimated $175 and bringing the position to 85 shares worth $16.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2073.
Quadrant Capital Group first reported a position in JAZZ in Q2 2015 and has held it in 42 quarters since. The position peaked at $256K in Q1 2025. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.
- Quadrant Capital Group held 85 shares of Jazz Pharmaceuticals worth $16.1K as of Q1 2026.
- Quadrant Capital Group bought 1 Jazz Pharmaceuticals share in Q1 2026, an estimated $175.
- Jazz Pharmaceuticals made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #2073 holding.
- Quadrant Capital Group first reported a position in Jazz Pharmaceuticals in Q2 2015 and has held it in 42 quarters since.
- Quadrant Capital Group's Jazz Pharmaceuticals position peaked at $256K in Q1 2025.
- 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.
Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.